ES2423993T3 - Proteínas HLA-G y usos farmacéuticos de las mismas - Google Patents

Proteínas HLA-G y usos farmacéuticos de las mismas Download PDF

Info

Publication number
ES2423993T3
ES2423993T3 ES09747827T ES09747827T ES2423993T3 ES 2423993 T3 ES2423993 T3 ES 2423993T3 ES 09747827 T ES09747827 T ES 09747827T ES 09747827 T ES09747827 T ES 09747827T ES 2423993 T3 ES2423993 T3 ES 2423993T3
Authority
ES
Spain
Prior art keywords
hla
polypeptide
sequence
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09747827T
Other languages
English (en)
Spanish (es)
Inventor
Benoit Favier
Edgardo D. Carosella
Joël Lemaoult
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HLA G Tech
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Commissariat a lEnergie Atomique CEA
HLA G Tech
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, HLA G Tech, Commissariat à l'Énergie Atomique et Aux Énergies Alternatives filed Critical Commissariat a lEnergie Atomique CEA
Application granted granted Critical
Publication of ES2423993T3 publication Critical patent/ES2423993T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
ES09747827T 2008-11-07 2009-11-04 Proteínas HLA-G y usos farmacéuticos de las mismas Active ES2423993T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US112804P 1998-12-18
EP08168675A EP2184070A1 (en) 2008-11-07 2008-11-07 HLA-G proteins and pharmaceutical uses thereof
EP08168675 2008-11-07
US11280408P 2008-11-10 2008-11-10
PCT/EP2009/064575 WO2010052228A1 (en) 2008-11-07 2009-11-04 Hla-g proteins and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
ES2423993T3 true ES2423993T3 (es) 2013-09-26

Family

ID=40673439

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09747827T Active ES2423993T3 (es) 2008-11-07 2009-11-04 Proteínas HLA-G y usos farmacéuticos de las mismas

Country Status (8)

Country Link
US (1) US20110268737A1 (enExample)
EP (2) EP2184070A1 (enExample)
JP (1) JP2012507994A (enExample)
CA (1) CA2742517A1 (enExample)
DK (1) DK2352509T3 (enExample)
ES (1) ES2423993T3 (enExample)
PT (1) PT2352509E (enExample)
WO (1) WO2010052228A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120177671A1 (en) * 2009-06-18 2012-07-12 Hla-G Technologies Hla-g alpha 1 multimers and pharmaceutical uses thereof
US9359424B2 (en) * 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
EA038705B1 (ru) * 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
SG11201408530YA (en) 2012-08-02 2015-03-30 Hoffmann La Roche Method for producing monomeric and multimeric molecules and uses thereof
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
AU2015209540B2 (en) * 2014-01-21 2021-05-13 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive T-cell immunomonitoring
JP6416480B2 (ja) * 2014-01-29 2018-10-31 国立大学法人北海道大学 関節リウマチまたはその関連疾患の予防または治療剤
US9765330B1 (en) 2015-01-09 2017-09-19 Nant Holdings Ip, Llc Compositions and methods for reduction of allograft recognition and rejection
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
CA3025681A1 (en) * 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
CA3027428A1 (en) * 2016-06-14 2017-12-21 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2021080171A (ja) * 2018-03-13 2021-05-27 国立大学法人北海道大学 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
US6790638B1 (en) 1998-02-20 2004-09-14 Commissariat A L'energie Atomique Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
FR2794977B1 (fr) 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
FR2810047B1 (fr) 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
WO2007011044A1 (ja) 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders

Also Published As

Publication number Publication date
WO2010052228A1 (en) 2010-05-14
DK2352509T3 (da) 2013-08-12
CA2742517A1 (en) 2010-05-14
EP2352509B1 (en) 2013-05-15
EP2184070A1 (en) 2010-05-12
US20110268737A1 (en) 2011-11-03
EP2352509A1 (en) 2011-08-10
PT2352509E (pt) 2013-08-27
JP2012507994A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
EP2352509B1 (en) Hla-g proteins and pharmaceutical uses thereof
AU2017312361B2 (en) T cell receptors and immune therapy using the same
US11401318B2 (en) Multimeric polypeptides of HLA-G including at least two alpha3 domains and pharmaceutical uses thereof
EP2184297A1 (en) HLA-G polypeptides and pharmaceutical uses thereof
AU2020336230A1 (en) Methods and compositions for the modification and delivery of lymphocytes
US12527875B2 (en) Methods for treating graft versus host disease
EP2264067A1 (en) HLA-G alpha 1 multimers and pharmaceutical uses thereof
KR102381854B1 (ko) T 세포 수용체 및 이를 사용하는 면역 요법
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
CN112236159B (zh) Oca-b肽缀合物和治疗方法
EP4067371A1 (en) T-cell receptors specific for hepatitis c virus peptides
CA3268631A1 (en) Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof